U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H20ClNO2
Molecular Weight 317.81
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SKF-83959

SMILES

CN1CCC2=C(C=C(O)C(O)=C2Cl)C(C1)C3=CC(C)=CC=C3

InChI

InChIKey=JXMYTVOBSFOHAF-UHFFFAOYSA-N
InChI=1S/C18H20ClNO2/c1-11-4-3-5-12(8-11)15-10-20(2)7-6-13-14(15)9-16(21)18(22)17(13)19/h3-5,8-9,15,21-22H,6-7,10H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C18H20ClNO2
Molecular Weight 317.81
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12675914 | https://www.ncbi.nlm.nih.gov/pubmed/17553535 | https://www.ncbi.nlm.nih.gov/pubmed/23892272

SKF83959 is a benzodiazepine derivative which acts as an agonist of D1 receptor. Activation of D1 receptors by SKF83959 fails to stimulate adenylyl cyclase and inhibits the stimulation of adenylyl cyclase induced by dopamine but stimulates phosphatidylinositol 4,5-biphosphate hydrolysis in membranes of frontal cortex. SKF83959 was identified as a specific agonist for the heteromer D1/D2 complex. SKF83959 elicit anti-parkinsonism effects in monkeys and rodents. In lower concentrations, SKF83959 inhibits serotonin, norepinephrine and dopamine transporters and is an allosteric regulator of sigma 1 receptor. The compound has demonstrated activity in a preclinical model of depression.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P21728
Gene ID: 1812.0
Gene Symbol: DRD1
Target Organism: Homo sapiens (Human)
0.66 nM [IC50]
Target ID: Q99720|||Q7Z653
Gene ID: 10280.0
Gene Symbol: SIGMAR1
Target Organism: Homo sapiens (Human)
Target ID: P23975
Gene ID: 6530.0
Gene Symbol: SLC6A2
Target Organism: Homo sapiens (Human)
0.6 µM [Ki]
Target ID: P31645
Gene ID: 6532.0
Gene Symbol: SLC6A4
Target Organism: Homo sapiens (Human)
1.43 µM [Ki]
Target ID: Q01959
Gene ID: 6531.0
Gene Symbol: SLC6A3
Target Organism: Homo sapiens (Human)
9.01 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.
2015-04-15
Activation of phosphatidylinositol-linked novel D1 dopamine receptors inhibits high-voltage-activated Ca2+ currents in primary cultured striatal neurons.
2009-05
D5 dopamine receptors are required for dopaminergic activation of phospholipase C.
2009-03
Activity-dependent modulation of limbic dopamine D3 receptors by CaMKII.
2009-02-12
Dopamine profoundly suppresses excitatory transmission in neonatal rat hippocampus via phosphatidylinositol-linked D1-like receptor.
2006
Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists.
2005-10
Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions.
2004-12
Regulation of cyclin-dependent kinase 5 and calcium/calmodulin-dependent protein kinase II by phosphatidylinositol-linked dopamine receptor in rat brain.
2004-12
Modification by dopaminergic drugs of choice behavior under concurrent schedules of intravenous saline and food delivery in monkeys.
2004-01
Prefrontal, accumbal [shell] and ventral striatal mechanisms in jaw movements and non-cyclase-coupled dopamine D1-like receptors.
2003-07-18
Ventral striatal vs. accumbal (shell) mechanisms and non-cyclase-coupled dopamine D(1)-like receptors in jaw movements.
2001-07-06
Topographical assessment and pharmacological characterization of orofacial movements in mice: dopamine D(1)-like vs. D(2)-like receptor regulation.
2001-04-20
Patents

Sample Use Guides

In a rat model of Parkinson's disease, SKF83959 was administered intraperitoneally at 0.5 mg/kg.
Route of Administration: Intraperitoneal
In Vitro Use Guide
[3H]SCH 23390 (72-80 Ci/mmol) was used as a radioligand to label dopamine D1 receptor. Rat striatal membranes were isolated in 50 mM K-phosphate buffer at pH 7.4 by homogenization and centrifugation. Membrane suspensions were incubated with 0.2 nM [3H]SCH23390 in a volume of 2.2 ml (1 mg original tissue) at 30°C for 60 min. After incubation, the samples were filtered through Whatman GF/F filters. Specific binding was defined as the difference in radioactivity obtained in the absence and the presence of 0.1 uM of cis(Z)-flupentixol. SKF83959 displaced [3H]SCH 23390 with IC50 of 0.66 nM.
Substance Class Chemical
Created
by admin
on Tue Apr 01 16:21:04 GMT 2025
Edited
by admin
on Tue Apr 01 16:21:04 GMT 2025
Record UNII
8CJ9F3C4Q0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SKF-83959
Common Name English
J489.412J
Preferred Name English
6-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-1-(3-METHYLPHENYL)-1H-3-BENZAZEPINE-7,8-DIOL
Systematic Name English
1H-3-BENZAZEPINE-7,8-DIOL, 6-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-1-(3-METHYLPHENYL)-
Systematic Name English
Code System Code Type Description
WIKIPEDIA
SKF-83,959
Created by admin on Tue Apr 01 16:21:04 GMT 2025 , Edited by admin on Tue Apr 01 16:21:04 GMT 2025
PRIMARY
CAS
80751-85-5
Created by admin on Tue Apr 01 16:21:04 GMT 2025 , Edited by admin on Tue Apr 01 16:21:04 GMT 2025
PRIMARY
PUBCHEM
133538
Created by admin on Tue Apr 01 16:21:04 GMT 2025 , Edited by admin on Tue Apr 01 16:21:04 GMT 2025
PRIMARY
FDA UNII
8CJ9F3C4Q0
Created by admin on Tue Apr 01 16:21:04 GMT 2025 , Edited by admin on Tue Apr 01 16:21:04 GMT 2025
PRIMARY
EPA CompTox
DTXSID8043818
Created by admin on Tue Apr 01 16:21:04 GMT 2025 , Edited by admin on Tue Apr 01 16:21:04 GMT 2025
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY